Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough.

NCT02175914 is registered in ClinicalTrials.gov with michal roll as lead sponsor.

NCT NCT02175914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough.
Lead sponsor
michal roll
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2014
Completion date
June 30, 2016
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fap-familial adenomatous polyposis